Homology Medicines, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022.
According to the Homology lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Homology Medicines, Inc.”
If you suffered a loss in Homology you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.